Status:
COMPLETED
Platelet Transfusion Refractoriness
Lead Sponsor:
Institut de cancérologie Strasbourg Europe
Conditions:
Platelet Transfusion Refractoriness
Eligibility:
All Genders
18+ years
Brief Summary
Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by ineffic...
Detailed Description
A preliminary study has shown different isotypes of anti-HLA I in patients with Platelet Transfusion Refractoriness. Our hypothesis is that the type of anti-HLA I antibodies (recognised epitope, quant...
Eligibility Criteria
Inclusion
- Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion.
Exclusion
- Patient under guardianship
- Minor patient
Key Trial Info
Start Date :
February 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 8 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05399693
Start Date
February 2 2022
End Date
August 8 2023
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de cancérologie Strasbourg Europe
Strasbourg, France